All companies
Visit website
TACTOGEN
OperatingTactogen, Inc.
Healthcare · Founded 2020
Developing new MDMA-like medicines for effective prescription mental wellness
Valuation cap ⓘ
$80.0M
As of Jan 2023 · from TACTOGEN Future Equity SAFE 1 · a SAFE/note conversion ceiling, not a priced valuation
Total raised
$92,942
Across 1 round since 2022
Latest share price
$1.00
TACTOGEN Future Equity SAFE 1 offering price
Financials
FY2020–FY2024 · from SEC filings · hover any figure for its source$0
−$429K
2020
$0
−$2.5M
2021
$0
−$2.6M
2023
$0
−$3.1M
2024
RevenueNet income — beside revenue when positive, below the line when a loss
Metric
FY2020
FY2021
FY2023
FY2024
Income statement
Revenue
$0
$0
$0
$0
Cost of goods sold
$0
$0
$0
$0
Net income
-$428,556
-$2,483,543
-$2,606,314
-$3,077,857
Taxes paid
$0
$0
$34,941
$46,695
Balance sheet
Cash
$733,443
$1,784,371
$1,779,166
$3,679,982
Accounts receivable
$0
$8,958
$0
$0
Total assets
$743,111
$1,799,821
$962,109
$1,383,600
Short-term debt
$55,689
$136,981
$0
$0
Long-term debt
$0
$0
$0
$0
Total liabilities
$55,689
$136,981
$0
$0
Other
Headcount
—
4
—
5
Figures as reported by the issuer in the filing shown on hover. Each year’s pill shows the assurance level of its filed statements — audited, reviewed (CPA review, less than an audit), or unaudited; no pill means the filing didn’t state one. Headcount is the filing’s point-in-time count, not a year-end average. Manually corrected figures are marked “Corrected”.
Valuation over rounds
Post-money = pre-money + amount raised · caps marked$80.0M
Valuation cap
TACTOGEN Future Equity SAFE 1
A dashed amber step is a SAFE/note valuation cap — a conversion ceiling agreed for that instrument, not a priced valuation of the company. Steps are not comparable across bases.
Fundraising history
Raised $92.9K / $5MInvestors 158Valuation cap $80M
Reg CF annual-report compliance
Not requiredFewer than 300 holders of record
Filed 1 of 4 annual reports (FY2022–FY2025)
158 investors
holder-count proxy
Reg CF issuers must file a Form C-AR each year until a Rule 202(b) termination trigger is met.
SEC filings
Source: ManualCIK 0001947054Share price $1.00
About this data. Figures are compiled from public sources — SEC EDGAR filings (Form C, C-AR, 1-A, 1-K) and funding-platform pages — and may be delayed, incomplete, or restated by the issuer. Financial statements are as reported by the issuer; each year is labeled with its assurance level (audited / reviewed / unaudited). A valuation cap is the conversion ceiling of a SAFE or convertible note, not an agreed company valuation; post-money figures are computed as pre-money plus amount raised and are not a traded price. Crowdonomics is not a broker-dealer, funding portal, or investment adviser; nothing here is investment advice or an offer to sell securities. Verify all figures against the linked EDGAR filings.